Tokio Marine Asset Management Co. Ltd. Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Tokio Marine Asset Management Co. Ltd. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,508 shares of the medical research company’s stock after purchasing an additional 240 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in IQVIA were worth $1,082,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the third quarter valued at $27,000. Park Place Capital Corp bought a new position in IQVIA during the 3rd quarter valued at $28,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Synergy Asset Management LLC bought a new position in IQVIA during the 4th quarter valued at $33,000. Finally, Assetmark Inc. boosted its stake in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the topic of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 11th. Bank of America dropped their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Truist Financial dropped their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $254.53.

IQVIA Stock Down 1.0 %

IQVIA stock opened at $199.34 on Tuesday. The stock has a market cap of $36.18 billion, a price-to-earnings ratio of 26.16, a PEG ratio of 2.15 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company’s 50-day moving average price is $200.41 and its two-hundred day moving average price is $220.32. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.